Ionis Pharmaceuticals (NASDAQ:IONS) Earns Outperform Rating from William Blair

Ionis Pharmaceuticals (NASDAQ:IONS)‘s stock had its “outperform” rating reaffirmed by stock analysts at William Blair in a report issued on Friday,RTT News reports. William Blair also issued estimates for Ionis Pharmaceuticals’ FY2028 earnings at $2.07 EPS.

Several other equities research analysts also recently weighed in on IONS. Piper Sandler reduced their target price on shares of Ionis Pharmaceuticals from $65.00 to $62.00 and set an “overweight” rating on the stock in a research note on Thursday, November 14th. Needham & Company LLC restated a “buy” rating and set a $60.00 target price on shares of Ionis Pharmaceuticals in a research report on Thursday, November 7th. Guggenheim decreased their price target on Ionis Pharmaceuticals from $70.00 to $65.00 and set a “buy” rating for the company in a research note on Wednesday, October 9th. StockNews.com downgraded Ionis Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, November 12th. Finally, Wells Fargo & Company lowered their target price on shares of Ionis Pharmaceuticals from $82.00 to $77.00 and set an “overweight” rating for the company in a research note on Thursday, November 7th. Two research analysts have rated the stock with a sell rating, five have given a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $60.65.

Ionis Pharmaceuticals Trading Up 0.1 %

IONS stock opened at $35.63 on Friday. The firm has a market cap of $5.63 billion, a PE ratio of -14.60 and a beta of 0.35. The firm has a fifty day moving average price of $37.38 and a 200 day moving average price of $42.25. The company has a debt-to-equity ratio of 1.86, a quick ratio of 8.82 and a current ratio of 8.91. Ionis Pharmaceuticals has a fifty-two week low of $33.33 and a fifty-two week high of $54.44.

Insiders Place Their Bets

In other Ionis Pharmaceuticals news, EVP Eric Swayze sold 1,194 shares of the company’s stock in a transaction on Tuesday, November 12th. The stock was sold at an average price of $37.92, for a total value of $45,276.48. Following the completion of the sale, the executive vice president now directly owns 33,713 shares in the company, valued at $1,278,396.96. This represents a 3.42 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Brett P. Monia sold 6,630 shares of Ionis Pharmaceuticals stock in a transaction on Tuesday, November 12th. The stock was sold at an average price of $38.05, for a total value of $252,271.50. Following the transaction, the chief executive officer now owns 167,393 shares in the company, valued at approximately $6,369,303.65. This represents a 3.81 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 7,877 shares of company stock valued at $299,578 in the last 90 days. 2.71% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of IONS. nVerses Capital LLC acquired a new position in Ionis Pharmaceuticals during the 2nd quarter worth about $29,000. GAMMA Investing LLC grew its holdings in shares of Ionis Pharmaceuticals by 83.9% in the third quarter. GAMMA Investing LLC now owns 664 shares of the company’s stock valued at $27,000 after purchasing an additional 303 shares in the last quarter. Itau Unibanco Holding S.A. purchased a new stake in Ionis Pharmaceuticals during the 2nd quarter worth approximately $37,000. Capital Performance Advisors LLP acquired a new stake in Ionis Pharmaceuticals during the 3rd quarter worth approximately $40,000. Finally, Prospera Private Wealth LLC acquired a new position in shares of Ionis Pharmaceuticals in the third quarter worth $42,000. Hedge funds and other institutional investors own 93.86% of the company’s stock.

Ionis Pharmaceuticals Company Profile

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy.